Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 310-290-3 | CAS number: 161907-80-8
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
A discussion paper on basic toxicokinetics including references for assessment of absorption, distribution, metabolism, potential for accumulation and excretion is attached. A summary is provided below.
Absorption
Based on the physicochemical characters (large MW, high water solubility, and low Kow), low acute oral toxicity and high repeated oral dose NOAEL (=380 mg/kg/day) of B-TTEGME in rats, it could be presumed that oral absorption of B-TTEGME is very low. Oral absorption of B-TTEGME however is evident from the slight effects (very slight centrilobular hypertrophy) that was observed in rats when orally exposed for 28 days.
The low vapour pressure of B-TTEGME (18.7 hPa at 20°C for B-TTEGME ; 120 Pa for B-TEGME) indicates it is non-volatile at room temperature, consistent with low LogPow (-4,37 for B-TEGME; for the longer chain lengths, lower LogPow are expected). Based on this, exposure of B-TTEGME through inhalation is unlikely.
Dermal penetration of B-TTEGME is expected to be very limited based on very low acute dermal toxicity (LD50>1520 mg/kg for B-TTEGME and >2000 mg/kg for B-TEGME), no dermal irritation, or sensitisation. The rate of dermal penetration of B-TTEGME has been predicted to be very low by Dermwin version 2.0 (5.59e-003 and 6.77e-004 mg/kg-day, respectively for B-TEGME and B-TetraEGME).
Distribution
Based on the physicochemical properties (low Kow and high water solubility), B-TTEGME is expected to have limited distribution and to remain only in the body water upon absorption.
Accumulation
Based on the high molecular weight, complete miscibility with water and very low lipohilicity (Kow), the systemically absorbed B-TTEGME is expected to eliminate from the body quite rapidly with low to no bioaccumulation.
Metabolism
Metabolism of B-TTEGME is expected from the increase in liver weight of the rats repeatedly orally exposed to B-TTEGME. Increase in liver weight and hypertrophy is often related to enzyme induction and metabolism of the test material in the liver. This compound would be expected to undergo oxidative O-dealkylation to afford smaller molecular weight glycol and carboxylic acid metabolites, as has been shown for other polyglycols and glycol ethers such as diethylene glycol and dipropylene glycol methyl ether.
Excretion
The systemically absorbed B-TTEGME is expected to be rapidly excreted through urine upon metabolism or through bile if remained unmetabolized or conjugated with phase II enzymes as the higher molecular weight compounds from B-TTEGME are preferably excreted through bile.Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
